Hide metadata

dc.date.accessioned2013-03-12T12:12:32Z
dc.date.available2013-03-12T12:12:32Z
dc.date.issued2010en_US
dc.date.submitted2011-02-15en_US
dc.identifier.citationHøie, Lars Henrik. Cholesterol lowering effects of soy protein, and how denatured protein may increase the risk for cardiovascular disease. Doktoravhandling, University of Oslo, 2010en_US
dc.identifier.urihttp://hdl.handle.net/10852/27944
dc.description.abstractProteiner som kan øke risikoen for hjerte-karsykdom Lege og forsker Lars Henrik Høie og kollegaer på universitetssykehus i Norden og Tyskland har meget overraskende funnet at proteiner som er fremstilt med høy varme (ultra heat treatment, UHT) kan øke risikoen for hjerte-karsykdom. Forskningsresultatene kan være av stor betydning, fordi soya- og andre melkeprodukter som er UHT behandlet, brukes regelmessig av store konsumentgrupper. I sin avhandling har Lars Høie og medarbeidere vist at soyaprotein senker total- og LDL-kolesterol i blod, men at UHT-behandlet soyaprotein signifikant øker LDL- og total kolesterol med ca. 20% etter 8 ukers bruk. UHT-fremstilte melkeproteinbaserte produkter har gitt samme resultater. De overraskende funnene ble underbygget av en studie hvor et nytt soyaprotein ble utviklet som ikke var varmebehandlet, som signifikant reduserte risikofaktorene LDL- og total-kolesterol sammenlignet med andre soyaproteiner. Helsemyndighetene i USA og England har i h.h.v. 1999 og 2002 godtatt at man ved inntak av produkter som inneholder minst 25g soyaprotein per dag kan hevde at disse produktene kan redusere hjerte-karsykdom ved å senke kolesterol. Resultatene fra Høie og medarbeidere kan gjøre det ønskelig for helsemyndigheter å få dokumentasjon fra selskaper som produserer soyaproteiner, og fra produsenter av proteinbaserte drikkevarer og andre langtidsholdbare produkter, hvor proteinene fremstilles med høy varme. Studiene i denne avhandlingen er utført i samarbeid med forskere fra universitetssykehus i Berlin, Helsinki, København, Stockholm og Århus, og de proteinbaserte produktene er blitt fremstilt i England, Holland, Norge og Sverige.nor
dc.description.abstractProteins which may increase the risk for cardiovascular disease Soy protein has been documented to significantly reduce serum lipids, and the U.S. Food and Drug Administration (FDA) approved in 1999 that the intake of at least 25 g soy protein per day may prevent coronary artery disease by lowering cholesterol. The Joint Health Claims Initiative (JHCI) approved a similar health claim in the U.K. in 2002. The aims of this thesis were to confirm in randomized, controlled trials (RCT) that soy protein significantly lowers LDL and total cholesterol and other risk factors for cardiovascular disease (CVD), and how processing of protein influence serum lipids. Surprisingly, we have found that ultra heat treated (UHT) soy protein significantly increases blood lipids, with an almost 20% increase in both LDL and total cholesterol after 8 weeks intake of 25 g soy protein per day (p<0.001). The same increases in serum lipids were found in the UHT milk protein based control beverage (p<0.001). UHT proteins may thereby increase the risk for CVD. Our results are important, since UHT processed proteins are found in beverages regularly used by large consumer groups, including UHT produced milk and soy milk, and other protein based products for long term shelf life. The unexpected results were supported by a study in which we developed and studied a non-denatured soy protein, which significantly lowered LDL and total cholesterol compared to a commercially available isolated soy protein. Legislators, including the FDA and JHCI, may eventually revise their health claims for soy protein and make these claims more specific, based on processing and clinical data from manufacturers of such proteins and soy protein based products. The studies presented in this thesis have been performed at university hospitals in Berlin, Copenhagen, Helsinki, Stockholm and Aarhus, while the protein based product developments have been conducted in England, Holland, Norway and Sweden.eng
dc.language.isoengen_US
dc.relation.haspartArticle 1: Hermansen K, Søndergaard M, Høie LH, Carstensen M, Brock B.: Benefitial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects. Diabetes Care 2001; 24 (2): 228-233. The paper is removed from the thesis in DUO due to publisher restrictions. The published version is available at: https://doi.org/10.2337/diacare.24.2.228
dc.relation.haspartArticle 2: Puska P, Korpelainen V, Høie LH, Skovlund E, Smerud KT.: Isolated soy protein with standardized levels of isoflavones, cotyledon soy fibers and soy phospholipids improves plasma lipids in hypercholesterolemia: a double-blind, placebo-controlled trial of a yoghurt formulation. British Journal of Nutrition 2004; 91: 393-401. The published version of this paper is available at: https://doi.org/10.1079/BJN20031074
dc.relation.haspartArticle 3: Clausen P, Lindhardsen J, Høie LH, Stender S.: Treatment with Abacor, a soy based dietary supplement, further reduces plasma concentrations of total and low-density lipoprotein cholesterol in statin-treated hypercholesterolaemic patients. Innovative Food Science and Emerging Technologies 2004; 5: 377-383. The paper is removed from the thesis in DUO due to publisher restrictions. The published version is available at: https://doi.org/10.1016/j.ifset.2004.05.005
dc.relation.haspartArticle 4: Høie LH, Graubaum HJ, Harde A, Gruenwald J, Wernecke KD. Lipid-lowering effect of 2 dosages of a soy supplement in hypercholesterolemia. Advances in Therapy 2005; 22 (2): 175-186. The paper is removed from the thesis in DUO due to publisher restrictions. The published version is available at: https://doi.org/10.1007/BF02849888
dc.relation.haspartArticle 5: Høie LH, Sjøholm Å, Guldstrand M, Zunft HJF, Lueder W, Graubaum HJ, Gruenwald J.: Ultra heat treatment destroys cholesterol-lowering effect of soy protein. International Journal of Food Sciences and Nutrition 2006; 57 (7/8): 512-519. The paper is removed from the thesis in DUO due to publisher restrictions. The published version is available at: https://doi.org/10.1080/09637480601009059
dc.relation.haspartArticle 6: Høie LH, Guldstrand M, Sjøholm Å, Graubaum HJ, Gruenwald J, Zunft HJF, Lueder W.: Cholesterol-lowering effects of a new isolated soy protein with high levels of non-denatured protein in hypercholesterolemic patients. Advances in Therapy 2007; 24 (2): 439-447. The paper is removed from the thesis in DUO due to publisher restrictions. The published version is available at: https://doi.org/10.1007/BF02849913
dc.relation.urihttps://doi.org/10.2337/diacare.24.2.228
dc.relation.urihttps://doi.org/10.1079/BJN20031074
dc.relation.urihttps://doi.org/10.1016/j.ifset.2004.05.005
dc.relation.urihttps://doi.org/10.1007/BF02849888
dc.relation.urihttps://doi.org/10.1080/09637480601009059
dc.relation.urihttps://doi.org/10.1007/BF02849913
dc.titleCholesterol lowering effects of soy protein, and how denatured protein may increase the risk for cardiovascular diseaseen_US
dc.typeDoctoral thesisen_US
dc.date.updated2011-03-04en_US
dc.creator.authorHøie, Lars Henriken_US
dc.subject.nsiVDP::700en_US
cristin.unitcode130000en_US
cristin.unitnameMedisinske fakulteten_US
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&rft.au=Høie, Lars Henrik&rft.title=Cholesterol lowering effects of soy protein, and how denatured protein may increase the risk for cardiovascular disease&rft.inst=University of Oslo&rft.date=2010&rft.degree=Doktoravhandlingen_US
dc.identifier.urnURN:NBN:no-27065en_US
dc.type.documentDoktoravhandlingen_US
dc.identifier.duo112195en_US
dc.contributor.supervisorDag Bruusgaarden_US
dc.identifier.bibsys111941172en_US
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/27944/3/dravhandling-hoie.pdf


Files in this item

Appears in the following Collection

Hide metadata